James M. Leatherman

1.8k total citations
26 papers, 814 citations indexed

About

James M. Leatherman is a scholar working on Oncology, Immunology and Molecular Biology. According to data from OpenAlex, James M. Leatherman has authored 26 papers receiving a total of 814 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Oncology, 14 papers in Immunology and 13 papers in Molecular Biology. Recurrent topics in James M. Leatherman's work include Cancer Immunotherapy and Biomarkers (8 papers), Immunotherapy and Immune Responses (8 papers) and Single-cell and spatial transcriptomics (4 papers). James M. Leatherman is often cited by papers focused on Cancer Immunotherapy and Biomarkers (8 papers), Immunotherapy and Immune Responses (8 papers) and Single-cell and spatial transcriptomics (4 papers). James M. Leatherman collaborates with scholars based in United States, Slovakia and Germany. James M. Leatherman's co-authors include Elizabeth M. Jaffee, Leisha A. Emens, Todd D. Armstrong, Justin M. Asquith, Elizabeth A. Manning, Timothy R. Hansen, Daniel J. Hicklin, Jeremy B. Foote, Mark Yarchoan and Thomas W. Dubensky and has published in prestigious journals such as Journal of Clinical Oncology, Hepatology and Cancer Research.

In The Last Decade

James M. Leatherman

26 papers receiving 803 citations

Peers

James M. Leatherman
Chang Gon Kim South Korea
Haofan Jin China
Manami Shimomura Japan
Anna Kwilas United States
Michael Fehlings Singapore
Mevyn Nizard France
Xiuqi Wu China
Anne-Sophie Chrétien France
Jingwei Sun China
Daiki Fukuma Japan
Chang Gon Kim South Korea
James M. Leatherman
Citations per year, relative to James M. Leatherman James M. Leatherman (= 1×) peers Chang Gon Kim

Countries citing papers authored by James M. Leatherman

Since Specialization
Citations

This map shows the geographic impact of James M. Leatherman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by James M. Leatherman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites James M. Leatherman more than expected).

Fields of papers citing papers by James M. Leatherman

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by James M. Leatherman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by James M. Leatherman. The network helps show where James M. Leatherman may publish in the future.

Co-authorship network of co-authors of James M. Leatherman

This figure shows the co-authorship network connecting the top 25 collaborators of James M. Leatherman. A scholar is included among the top collaborators of James M. Leatherman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with James M. Leatherman. James M. Leatherman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Zabransky, Daniel J., Yash Chhabra, Mitchell E. Fane, et al.. (2024). Fibroblasts in the Aged Pancreas Drive Pancreatic Cancer Progression. Cancer Research. 84(8). 1221–1236. 13 indexed citations
2.
Maru, Saumya, Kathryn L. Howe, James M. Leatherman, et al.. (2024). Abstract B034: Antigen-presenting cancer-associated fibroblasts are found in immunotherapy-sensitive murine models of pancreatic ductal adenocarcinoma. Cancer Research. 84(2_Supplement). B034–B034. 1 indexed citations
3.
Gonzalez, Edgar R., Christine I. Rafie, Julie K. Jang, et al.. (2024). A new Neu—a syngeneic model of spontaneously metastatic HER2-positive breast cancer. Clinical & Experimental Metastasis. 41(5). 733–746. 2 indexed citations
4.
Huff, Amanda L., Jacob T. Mitchell, Emily F. Davis-Marcisak, et al.. (2023). CD4 T cell–activating neoantigens enhance personalized cancer vaccine efficacy. JCI Insight. 8(23). 14 indexed citations
5.
Sidiropoulos, Dimitrios N., Genevieve Stein-O’Brien, Ludmila Danilova, et al.. (2022). Integrated T cell cytometry metrics for immune-monitoring applications in immunotherapy clinical trials. JCI Insight. 7(19). 9 indexed citations
6.
Zabransky, Daniel J., Ludmila Danilova, James M. Leatherman, et al.. (2022). Profiling of syngeneic mouse HCC tumor models as a framework to understand anti–PD‐1 sensitive tumor microenvironments. Hepatology. 77(5). 1566–1579. 38 indexed citations
7.
Dennison, Lauren, Aditya Mohan, James M. Leatherman, et al.. (2021). Context-Dependent Immunomodulatory Effects of MEK Inhibition Are Enhanced with T-cell Agonist Therapy. Cancer Immunology Research. 9(10). 1187–1201. 17 indexed citations
8.
Torres, Evanthia T. Roussos, James M. Leatherman, Christine I. Rafie, et al.. (2021). 964MO Entinostat, nivolumab and ipilimumab in advanced HER2-negative breast cancer (ETCTN-9844). Annals of Oncology. 32. S833–S833. 4 indexed citations
9.
Yarchoan, Mark, Qingfeng Zhu, Jennifer N. Durham, et al.. (2021). Feasibility and efficacy of neoadjuvant cabozantinib and nivolumab in patients with borderline resectable or locally advanced hepatocellular carcinoma (HCC).. Journal of Clinical Oncology. 39(3_suppl). 335–335. 15 indexed citations
10.
Heumann, Thatcher, Marina Baretti, Elizabeth A. Sugar, et al.. (2021). 1470P Oral azacitidine (CC-486) in patients with resected pancreatic adenocarcinoma at high risk for recurrence. Annals of Oncology. 32. S1087–S1088. 1 indexed citations
11.
Ho, Won Jin, Ludmila Danilova, Su Jin Lim, et al.. (2020). Viral status, immune microenvironment and immunological response to checkpoint inhibitors in hepatocellular carcinoma. Journal for ImmunoTherapy of Cancer. 8(1). e000394–e000394. 47 indexed citations
12.
Gaillard, Stéphanie, Peng Huang, James M. Leatherman, et al.. (2020). A clinical study of tremelimumab alone or in combination with olaparib in patients with advanced epithelial ovarian cancer.. Journal of Clinical Oncology. 38(15_suppl). 6045–6045. 5 indexed citations
13.
Yarchoan, Mark, Won Jin Ho, Aditya Mohan, et al.. (2020). Effects of B cell–activating factor on tumor immunity. JCI Insight. 5(10). 33 indexed citations
14.
Foote, Jeremy B., Marleen Kok, James M. Leatherman, et al.. (2017). A STING Agonist Given with OX40 Receptor and PD-L1 Modulators Primes Immunity and Reduces Tumor Growth in Tolerized Mice. Cancer Immunology Research. 5(6). 468–479. 117 indexed citations
15.
Foote, Jeremy B., James M. Leatherman, Justin P. Edwards, et al.. (2017). Sorafenib combined with HER-2 targeted vaccination can promote effective T cell immunity in vivo. International Immunopharmacology. 46. 112–123. 31 indexed citations
16.
Emens, Leisha A., Ritu Gupta, James M. Leatherman, et al.. (2011). A feasibility study of combination therapy with trastuzumab (T), cyclophosphamide (CY), and an allogeneic GM-CSF-secreting breast tumor vaccine for the treatment of HER2+ metastatic breast cancer.. Journal of Clinical Oncology. 29(15_suppl). 2535–2535. 8 indexed citations
17.
Rajasekaran, Sigrid A., Daniel Wolle, Cromwell E. Espineda, et al.. (2010). Na,K-ATPase Subunits as Markers for Epithelial-Mesenchymal Transition in Cancer and Fibrosis. Molecular Cancer Therapeutics. 9(6). 1515–1524. 67 indexed citations
18.
19.
Manning, Elizabeth A., James M. Leatherman, Justin M. Asquith, et al.. (2007). A Vascular Endothelial Growth Factor Receptor-2 Inhibitor Enhances Antitumor Immunity through an Immune-Based Mechanism. Clinical Cancer Research. 13(13). 3951–3959. 158 indexed citations
20.
Mullin, James M., James M. Leatherman, Mary Carmen Valenzano, et al.. (2005). RasMutation Impairs Epithelial Barrier Function to a Wide Range of Nonelectrolytes. Molecular Biology of the Cell. 16(12). 5538–5550. 35 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Chang Gon Kim Breakdown of academic impact, for papers by Haofan Jin Breakdown of academic impact, for papers by Manami Shimomura Breakdown of academic impact, for papers by Anna Kwilas Breakdown of academic impact, for papers by Michael Fehlings Breakdown of academic impact, for papers by Mevyn Nizard Breakdown of academic impact, for papers by Xiuqi Wu Breakdown of academic impact, for papers by Anne-Sophie Chrétien Breakdown of academic impact, for papers by Jingwei Sun Breakdown of academic impact, for papers by Daiki Fukuma
Rankless by CCL
2026